Summary
In a 48-week, double-blind trial, 122 patients were randomly assigned to treatment with auranofin (60) and gold sodium thiomalate (GST) (62) at five centers. Both groups showed significant improvement (P<0.05) from baseline in parameters of disease activity. Results of the covariance analysis for all patients who completed the trial showed no significant differences (P<0.05) in efficacy between the two groups. The proportions of patients showing 50% or greater improvement in tender joints, swollen joints, activity index, severity of pain, general health rating, and erythrocyte sedimentation rate (ESR) were similar for both auranofin-treated and GST-treated patients who completed the 48-week trial. When all patients who entered the trial were evaluated, a slightly greater proportion of patients on auranofin had improved. Diarrhea occurred more frequently with auranofin (32%) compared to GST (19%), whereas rash and pruritus were twice as common in those patients treated with GST compared to those treated with auranofin. The withdrawal rate due to adverse reactions was 10% for auranofin vs 26% for GST. It was concluded that the efficacy of auranofin was comparable to that of injectable gold and was better tolerated, as evidenced by the lower withdrawal rate from adverse events for the auranofin patients.
Similar content being viewed by others
Abbreviations
- ARA:
-
American Rheumatism Association
- ESR:
-
Erythrocyte sedimentation rate
- GGT:
-
Gamma-glutamyl-transpeptidase
- GST:
-
Gold sodium thiomalate
- NSAID:
-
Nonsteroidal antiinflammatory drug
- RA:
-
Rheumatoid arthritis
- SGOT:
-
Serum-glutamate-oxalacetate transaminase
- SGPT:
-
Serum-glutamate-pyruvate transaminase
- WBC:
-
White blood count
References
Blodgett RC, Heuer MA, Pietrusko RG (1984) Auranofin: A unique oral chrysotherapeutic agent. Semin Arthritis Rheum 13 (3):255–273
Lansbury J (1972) Methods for evaluating rheumatoid arthritis. In: Hollander JL, McCarty DJ (eds) Arthritis and Allied Conditions, edn. 8, Lea and Febiger, Philadelphia, pp 419–437
Ropes MW, Bennett GA, Cobb S, et al. (1958) 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis 9:175–176
Schattenkirchner M, Kaik B, Müller-Fassbender H, et al. (1982) Auranofin and sodium aurothiomalate in the treatment of rheumatoid arthritis: A double-blind, comparative, multicenter study. J Rheumatol (Suppl 8) 9:184–189
Walz DT, Di Martino MJ, Griswold DE (1982) Comparative pharmacology and biological effects of different gold compounds. J Rheumatol (Suppl 8) 9:54–60
Ward JR, Williams HJ, Egger MJ, et al. (1983) Comparison of auranofin, gold sodium thiomalate, and placebo in the treatment of rheumatoid arthritis. Arthritis Rheum 26:1303–1315
Wenger ME, Alexander S, Bland JH, Blechman WJ (1983) Auranofin versus placebo in the treatment of rheumatoid arthritis. Am J Med 75 (6A):123–127
Author information
Authors and Affiliations
Additional information
Dedicated to Prof. Dr. N. Zöllner on the occasion of his 65th birthday
Rights and permissions
About this article
Cite this article
Schattenkirchner, M., Bröll, H., Kaik, B. et al. Auranofin and gold sodium thiomalate in the treatment of rheumatoid arthritis: A one-year, double-blind, comparative multicenter study. Klin Wochenschr 66, 167–174 (1988). https://doi.org/10.1007/BF01727786
Received:
Revised:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF01727786